0001104659-23-071204.txt : 20230614
0001104659-23-071204.hdr.sgml : 20230614
20230614161617
ACCESSION NUMBER: 0001104659-23-071204
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230609
FILED AS OF DATE: 20230614
DATE AS OF CHANGE: 20230614
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dudley Robert Michael
CENTRAL INDEX KEY: 0001854161
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40363
FILM NUMBER: 231014316
MAIL ADDRESS:
STREET 1: C/O TRANSCODE THERAPEUTICS
STREET 2: 6 LIBERTY SQUARE #2382
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Transcode Therapeutics, Inc.
CENTRAL INDEX KEY: 0001829635
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 811065054
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6 LIBERTY SQUARE
STREET 2: #2382
CITY: BOSTON
STATE: MA
ZIP: 02109
BUSINESS PHONE: 857-301-6857
MAIL ADDRESS:
STREET 1: 6 LIBERTY SQUARE
STREET 2: #2382
CITY: BOSTON
STATE: MA
ZIP: 02109
4/A
1
tm2318742-1_4aseq1.xml
OWNERSHIP DOCUMENT
X0407
4/A
2023-06-09
2023-06-13
0
0001829635
Transcode Therapeutics, Inc.
RNAZ
0001854161
Dudley Robert Michael
C/O TRANSCODE THERAPEUTICS, INC.
6 LIBERTY SQUARE, #2382
BOSTON
MA
02109
1
1
0
0
Chief Executive Officer
0
Common Stock
2023-06-09
4
P
0
19000
2.76
A
61155
D
Reflects the weighted average purchase price for shares of common stock purchased. Actual purchase prices for the shares purchased ranged from $2.675 to $2.85. The Reporting Person undertakes to provide TransCode Therapeutics, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission full information regarding the number of shares purchased at each separate price.
This Form 4/A amends the Form 4 originally filed on June 13, 2023 solely to correct the amount reported in Table I, Column 5. Due to an administrative error, the amount reported on the original Form 4 was not adjusted to reflect a 1-for-20 reverse stock split of the Company's common stock, which became effective as of May 22, 2023.
/s/ Thomas A. Fitzgerald, as Attorney-in-Fact
2023-06-14